Fre­quen­cy fol­lows Astel­las pact with $62M round to bankroll PhII of lead re­gen­er­a­tive drug

A few days ago Fre­quen­cy Ther­a­peu­tics got some high pro­file en­dorse­ment on its small mol­e­cule strat­e­gy for re­gen­er­a­tive med­i­cine, when Astel­las of­fered $80 mil­lion up­front to part­ner on their lead drug. As it turns out, the Japan­ese phar­ma wasn’t the on­ly one in­trigued by the plat­form and up­com­ing Phase II study of FX-322.

Per­cep­tive Ad­vi­sors has jumped in to lead a $62 mil­lion Se­ries C, which al­so drew Deer­field Man­age­ment, RTW In­vest­ments and Mizuho Se­cu­ri­ties Prin­ci­pal In­vest­ment. Po­laris, Tai­wa­nia, Ax­il and Co­Bro al­so dou­bled down on their ex­ist­ing bet.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER